OABI (OmniAb) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OABI OmniAb Inc OABI
72 GF Score
Price $2.03
GF Value $2.27
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is OmniAb Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

OABI
72GF Score
OmniAb Inc OABI
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is OmniAb (OABI) Overvalued in 2026?

Based on GuruFocus' analysis, OmniAb stock appears to be undervalued. The current stock price of $2.03 is trading 10.6% below its estimated GF Value™ of $2.27. GuruFocus considers OmniAb to be Modestly Undervalued.

Key valuation signals for OABI:

  • Short Ratio:
  • GF Value™: $2.27 vs. price of $2.03 (10.6% below fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the OABI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OmniAb Business Description

Address 5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
72GF Score

Get the complete analysis for OABI

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.03
Price
$2.27
GF Value